Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
AbstractThere has been a remarkable transformation in the treatment of chronic hepatitis C in recent years with the development of direct acting antiviral agents targeting virus encoded proteins important for viral replication including NS3/4A, NS5A and NS5B. These agents have shown high sustained viral response (SVR) rates of more than 90% in phase 2 and phase 3 clinical trials; however, this is slightly lower in real-life cohorts. Hepatitis C virus resistant variants are seen in most patients who do not achieve SVR due to selection and outgrowth of resistant hepatitis C virus variants within a given host. These resistance associated mutations depend on the class of direct-acting antiviral drugs used and also vary between hepatitis C virus genotypes and subtypes. The understanding of these mutations has a clear clinical implication in terms of choice and combination of drugs used. In this review, we describe mechanism of action of currently available drugs and summarize clinically relevant resistance data. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Ahmed, A.; Felmlee, D.J. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses 2015, 7, 6716-6729.
Ahmed A, Felmlee DJ. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses. 2015; 7(12):6716-6729.Chicago/Turabian Style
Ahmed, Asma; Felmlee, Daniel J. 2015. "Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals." Viruses 7, no. 12: 6716-6729.